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DOI 10.1016/j.stem.2009.02.010‘‘Guidelines and Techniques for the
Generation of Induced Pluripotent Stem
Cells’’ (Maherali and Hochedlinger, 2008)
is a timely and valuable review of this
rapidly progressing and multiple-disease-
relevant area of stem cell research. We
agree that criteria and standards are
important to allow for cross-lab data
comparisons to ensure that new con-
sensus-based interpretations are well
grounded. The criteria are especially rele-
vant for fundamental studies on the mech-
anisms of reprogramming and on interro-
gation into the pluripotent state. It is clear
from the recent published literature that
the breadth of investigators participating
in technology development in the iPSC
area should increase dramatically. New
translational energy and activity should
emerge by introducing iPSC technology
to as many different laboratories as
possible. Criteria that could be routinely
established in an average lab setting could
be beneficial to the field by promoting
speedy in vitro applications for iPSCs.
However, as one specific example, the
proposed criteria may not be fully required
for applications in which reprogrammed
human cell lines are used to model disease
processes in vitro, and to screen for novel
drugs or drug toxicity. It is expected that
many such cell lines from many different
human genetic backgrounds and disease
states will be generated in the near future.
To stimulate a broad discussion of the
fundamental minimal criteria that should
define these iPSC lines, we offer the
following comments.198 Cell Stem Cell 4, March 6, 2009 ª2009 ETeratoma Formation Is Not
Required for In Vitro Applications,
and Germline Transmission Is Not
a Feature of All Pluripotent Cells
Maherali and Hochedlinger agree that
complete characterization of every iPSC
line is not feasible and developed the
following minimal set of criteria for iPSC
characterization: (1) pluripotent stem cell
morphology and unlimited self-renewal,
(2) expression of pluripotency markers
and downregulation of differentiation
markers, (3) reprogramming factor inde-
pendence, and (4) ‘‘proof of functional
differentiation through the highest-strin-
gency test acceptable.’’ The most strin-
gent functional criteria are that mouse
iPSCs must be germline competent after
chimera formation, while human iPSCs
must form teratomas with tissues of all
three germ layers when transplanted to
immune-deficient mice. Human iPSC lines
appear to be less efficient at forming
teratomas and require more cells in
comparison to hESCs (Park et al., 2008),
suggesting that the teratoma assay
employs many recipient mice to define
the competence of perhaps a subset of
contributing iPSCs. Furthermore, the tera-
toma assay, at least in its commonly used
form, is qualitative in nature. In the context
of in vitro applications and analysis of
patient-specific iPSCs, is teratoma forma-
tion really the most appropriate assay?
We agree with the minimal criteria
proposed by Maherali and Hochedlinger,
except that we propose that cell lines
that fail at the most stringent functionallsevier Inc.level of generating teratomas or transmis-
sion through the germline may be equally
useful for in vitro studies. There are
currently robust protocols available to
drive hESCs toward early neuroectoderm,
mesoderm, and endoderm in vitro that
allow full quantitative assessment of
differentiation capacity (Murry and Keller,
2008). Application of these methods could
rapidly determine whether the lines retain
the fundamental criterion of differentiation
into the three primary germ layers or
had restricted differentiation capacity.
Importantly, as iPSC technology improves
with the development of therapeutically
compatible reprogramming methods, the
most desirable iPSCs to use for transplan-
tation might be those that donot form tera-
tomas in vivo while retaining the capacity
to efficiently generate curative cell types
in vitro. This possibility can only be deter-
mined if non-teratoma-forming iPSC lines
are fully studied in vitro. Finally, when
mouse iPSCs are generated as a proof of
principle for future human iPSC applica-
tions, the ability to generate germline
chimeras may not always be the most rele-
vant property. The equivalent experiments
cannot be conducted in the human setting
and contribution to the specialized germ
cell lineage is noninformative for in vitro
studies. Furthermore, future generation
of mouse iPSCs with properties similar
to pluripotent epiblast stem cells could
have increased relevance to human ESCs
and iPSCs (Rossant, 2008). Epiblast stem
cells do not contribute to chimeras and yet
show in vitro pluripotency, suggesting that
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entiation may be a useful functional crite-
rion for iPSCs that are developed for
in vitro applications.
The Utility of Reporter Constructs
We also wish to point out that Maherali
and Hochedlinger propose that human
iPSCs should be derived using morpho-
logical or live cell staining procedures
that require ‘‘a considerable degree
of ESC expertise’’ and that ‘‘selection
methods were unnecessary and actually
counterproductive.’’ For iPSC technology
to have its most profound impact, it is
important to simplify the entrance require-
ments to recruit more laboratories to
contribute new disease-specific lines
and in vitro applications to the field. While
we agree that iPSC lines can readily be
isolated by morphological criteria andlive cell staining, we contend that well-
designed reporters containing fluorescent
or selectable markers can facilitate isola-
tion and expansion of reprogrammed
colonies and would be critical for new
investigators in the field. They also have
utility for optimization of novel reprogram-
ming methods and can monitor the
presence of undifferentiated cells dur-
ing directed differentiation protocols.
Furthermore, looking into future thera-
peutic applications of iPSCs, reporter
constructs could be engineered to
encode a suicide gene to destroy residual
undifferentiated iPSCs ex vivo prior to
transplantation, or to track and ablate
any misbehaving cells that appear
in vivo in the patient.
In summary, we welcome a discussion
to establish a globally acceptable set of
fundamental criteria that define iPSCs forCell Stem Cin vitro applications. These criteria should
be compatible with rapid characterization
of the isolated iPSCs. In addition, develop-
ment of reagents that facilitate entry into
the field and that genetically modify iPSCs
for safe future transplantations should be
encouraged.
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